MX363807B - Formulacion liquida que comprende un compuesto neutralizante de gm-csf. - Google Patents
Formulacion liquida que comprende un compuesto neutralizante de gm-csf.Info
- Publication number
- MX363807B MX363807B MX2015005237A MX2015005237A MX363807B MX 363807 B MX363807 B MX 363807B MX 2015005237 A MX2015005237 A MX 2015005237A MX 2015005237 A MX2015005237 A MX 2015005237A MX 363807 B MX363807 B MX 363807B
- Authority
- MX
- Mexico
- Prior art keywords
- formulation
- csf
- liquid formulation
- disorders
- neutralizing compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261720892P | 2012-10-31 | 2012-10-31 | |
| EP12199191 | 2012-12-21 | ||
| PCT/EP2013/072761 WO2014068026A1 (en) | 2012-10-31 | 2013-10-31 | Liquid formulation comprising gm-csf neutralizing compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005237A MX2015005237A (es) | 2015-10-29 |
| MX363807B true MX363807B (es) | 2019-04-03 |
Family
ID=47504727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005237A MX363807B (es) | 2012-10-31 | 2013-10-31 | Formulacion liquida que comprende un compuesto neutralizante de gm-csf. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9919051B2 (https=) |
| EP (2) | EP2914290B1 (https=) |
| JP (1) | JP6346189B2 (https=) |
| KR (1) | KR102106914B1 (https=) |
| CN (1) | CN104768580B (https=) |
| AR (1) | AR093297A1 (https=) |
| AU (1) | AU2013340845B2 (https=) |
| BR (1) | BR112015009259B8 (https=) |
| CA (1) | CA2889307C (https=) |
| EA (1) | EA032829B1 (https=) |
| MX (1) | MX363807B (https=) |
| PH (1) | PH12015500864B1 (https=) |
| TW (1) | TWI639440B (https=) |
| WO (1) | WO2014068026A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10745475B2 (en) | 2013-08-30 | 2020-08-18 | Takeda Gmbh | Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics |
| KR102385802B1 (ko) * | 2014-05-07 | 2022-04-13 | 다케다 야쿠힝 고교 가부시키가이샤 | Gm-csf 중화 화합물을 포함하는 액체 제제 |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
| PT2946765T (pt) | 2014-05-23 | 2016-11-10 | Ares Trading Sa | Composição farmacêutica líquida |
| SG11201901789WA (en) * | 2016-09-19 | 2019-03-28 | I Mab | Anti-gm-csf antibodies and uses thereof |
| BR112019018022A2 (pt) * | 2017-03-01 | 2020-06-02 | Medimmune Limited | Formulações de anticorpos monoclonais |
| CN107167613B (zh) * | 2017-06-22 | 2018-10-02 | 深圳清华大学研究院 | 用于等离子体金芯片的蛋白点样缓冲液 |
| WO2021011404A1 (en) * | 2019-07-12 | 2021-01-21 | Contrafect Corporation | Therapeutic protein formulations comprising antibodies and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
| US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP0158487B1 (en) | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
| GB8624899D0 (en) | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5070013A (en) | 1988-05-31 | 1991-12-03 | Schering Corporation | Immunochemical assay for human granulocyte-macrophage colony stimulating factor |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
| US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| US6309636B1 (en) | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| US7101551B2 (en) | 2000-02-14 | 2006-09-05 | Mitsubishi Pharma Corporation | Remedies for hepatitis C |
| MXPA04000747A (es) * | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| JP2006500905A (ja) | 2002-02-13 | 2006-01-12 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | ヒト化ｇｍ−ｃｓｆ抗体 |
| SI1478394T1 (sl) | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| US9415102B2 (en) * | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| AU2005249360B2 (en) * | 2004-04-12 | 2011-07-21 | Medimmune, Llc | Anti-IL-9 antibody formulations and uses thereof |
| ATE435238T1 (de) | 2004-05-05 | 2009-07-15 | Micromet Ag | Herstellung eines einkettigen fv antikörperfragments |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US20060177436A1 (en) | 2004-12-16 | 2006-08-10 | Genentech, Inc. | Methods for Treating Autoimmune Disorders |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| BRPI0608281B8 (pt) * | 2005-04-18 | 2021-05-25 | Amgen Res Munich Gmbh | anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende |
| RU2447085C2 (ru) | 2005-05-18 | 2012-04-10 | МорфоСис АГ | Анти-gm-csf антитела и их применение |
| JP4736037B2 (ja) | 2005-10-26 | 2011-07-27 | 株式会社イーベック | ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分 |
| CA2638811A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| US7741450B2 (en) | 2006-02-08 | 2010-06-22 | Morphotek Inc. | Antibodies to GM-CSF |
| MX2008012291A (es) | 2006-03-27 | 2009-01-12 | Medimmune Ltd | Miembro que enlaza al receptor gm-csf. |
| EP2101780B1 (en) * | 2006-11-21 | 2013-10-09 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
| EP2170268A2 (en) * | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| CN104072613A (zh) | 2007-11-13 | 2014-10-01 | Evec股份有限公司 | 与hGM-CSF结合的单克隆抗体及包含它的药物组合物 |
| WO2009134805A2 (en) | 2008-04-28 | 2009-11-05 | Kalobios Pharmaceuticals, Inc. | Antibodies to granulocyte-macrophage colony-stimulating factor |
| CA2717987C (en) | 2008-04-29 | 2018-11-13 | Micromet Ag | Inhibitors of gm-csf and il-17 for therapy |
| CA2747206C (en) | 2008-12-22 | 2018-04-24 | The University Of Melbourne | Pain treatment |
| US20120116059A1 (en) | 2009-05-05 | 2012-05-10 | Morphosys Ag | Treatment For M Treatment For Multiple Sclerosis |
| EP2458990B1 (en) * | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| BR112012013148A2 (pt) * | 2009-12-29 | 2017-03-21 | F Hoffmann - La Roche Ag | formulação farmacêutica e uso |
| EP3409289B1 (en) * | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| MA37946B1 (fr) * | 2012-09-20 | 2018-09-28 | Morphosys Ag | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde |
| WO2014068029A1 (en) * | 2012-10-31 | 2014-05-08 | Takeda Gmbh | Lyophilized formulation comprising gm-csf neutralizing compound |
-
2013
- 2013-10-30 AR ARP130103964A patent/AR093297A1/es not_active Application Discontinuation
- 2013-10-31 JP JP2015538509A patent/JP6346189B2/ja active Active
- 2013-10-31 CA CA2889307A patent/CA2889307C/en active Active
- 2013-10-31 EP EP13798590.9A patent/EP2914290B1/en active Active
- 2013-10-31 MX MX2015005237A patent/MX363807B/es active IP Right Grant
- 2013-10-31 EP EP20166154.3A patent/EP3744344A1/en not_active Withdrawn
- 2013-10-31 US US14/429,204 patent/US9919051B2/en active Active
- 2013-10-31 KR KR1020157008428A patent/KR102106914B1/ko active Active
- 2013-10-31 TW TW102139662A patent/TWI639440B/zh active
- 2013-10-31 BR BR112015009259A patent/BR112015009259B8/pt active IP Right Grant
- 2013-10-31 AU AU2013340845A patent/AU2013340845B2/en active Active
- 2013-10-31 CN CN201380056759.5A patent/CN104768580B/zh active Active
- 2013-10-31 WO PCT/EP2013/072761 patent/WO2014068026A1/en not_active Ceased
- 2013-10-31 EA EA201590509A patent/EA032829B1/ru not_active IP Right Cessation
-
2015
- 2015-04-17 PH PH12015500864A patent/PH12015500864B1/en unknown
-
2018
- 2018-03-15 US US15/922,777 patent/US10758621B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PH12015500864A1 (en) | 2015-06-22 |
| US10758621B2 (en) | 2020-09-01 |
| AU2013340845B2 (en) | 2018-02-22 |
| AU2013340845A1 (en) | 2015-03-26 |
| EP3744344A1 (en) | 2020-12-02 |
| KR20150075083A (ko) | 2015-07-02 |
| PH12015500864B1 (en) | 2015-06-22 |
| KR102106914B1 (ko) | 2020-05-08 |
| EA032829B1 (ru) | 2019-07-31 |
| EP2914290B1 (en) | 2020-04-01 |
| AR093297A1 (es) | 2015-05-27 |
| WO2014068026A1 (en) | 2014-05-08 |
| US9919051B2 (en) | 2018-03-20 |
| CN104768580A (zh) | 2015-07-08 |
| BR112015009259B1 (pt) | 2022-05-17 |
| BR112015009259A2 (https=) | 2017-08-22 |
| BR112015009259B8 (pt) | 2022-08-23 |
| EP2914290A1 (en) | 2015-09-09 |
| JP2015536931A (ja) | 2015-12-24 |
| TW201438735A (zh) | 2014-10-16 |
| CN104768580B (zh) | 2018-11-02 |
| JP6346189B2 (ja) | 2018-06-20 |
| MX2015005237A (es) | 2015-10-29 |
| US20180207278A1 (en) | 2018-07-26 |
| TWI639440B (zh) | 2018-11-01 |
| EA201590509A1 (ru) | 2015-10-30 |
| CA2889307C (en) | 2021-11-23 |
| US20150314001A1 (en) | 2015-11-05 |
| HK1214761A1 (en) | 2016-08-05 |
| CA2889307A1 (en) | 2014-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500864A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| PH12016502100A1 (en) | Liquid formulation comprising gm-csf neutralizing compound | |
| MX377553B (es) | Composicion farmaceutica estable y metodos de uso de la misma. | |
| DOP2013000105A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
| BR112015014034A2 (pt) | inibidores de irak e usos dos mesmos | |
| NZ709486A (en) | Solid solution compositions and use in chronic inflammation | |
| MX2012015096A (es) | Compuestos heterociclicos fusionados como moduladores del canal ion. | |
| BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
| MX344732B (es) | Formulacion estable de mia/cd-rap. | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| TN2016000005A1 (en) | Substituted pyrazolo-pyridinamines | |
| BR112014000773A8 (pt) | Composições de nicotinamida e uso terapêutico das mesmas | |
| JOP20170125A1 (ar) | مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] (1h-1، 2، 3-تريازول-4-يل) ميثانون | |
| IN2014MN00929A (https=) | ||
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов | |
| UY31587A1 (es) | Derivados de n-heterociclico-imidazo[1,2-a]piridina-2-carboxamidas, su preparacion y su aplicacion en terapéutica. | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| UY31592A1 (es) | Compuestos de n-fenil-imidazo[1,2-a]piridin-2-carboxamidas, su preparacion y su aplicacion en terapéutica | |
| UY32894A (es) | Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica | |
| EA201591218A1 (ru) | Способы и композиции для введения оксибутинина | |
| MX2015007347A (es) | Composiciones de gel. | |
| PL404379A1 (pl) | Maść | |
| PH12015502560A1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease | |
| TH168550A (th) | สูตรผสมของเหลวซึ่งประกอบรวมด้วยสารประกอบลบล้างฤทธิ์ gm-csf | |
| EA201500366A1 (ru) | Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |